The estimated Net Worth of James E Utts is at least 925 千$ dollars as of 24 February 2005. James Utts owns over 17,000 units of Baxter International stock worth over 925,201$ and over the last 20 years James sold BAX stock worth over 0$.
James has made over 2 trades of the Baxter International stock since 2005, according to the Form 4 filled with the SEC. Most recently James exercised 8,592 units of BAX stock worth 142,541$ on 27 April 2005.
The largest trade James's ever made was exercising 17,000 units of Baxter International stock on 24 February 2005 worth over 282,030$. On average, James trades about 3,199 units every 8 days since 2004. As of 24 February 2005 James still owns at least 23,560 units of Baxter International stock.
You can see the complete history of James Utts stock trades at the bottom of the page.
James's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60035.
Over the last 22 years, insiders at Baxter International have traded over 966,809,165$ worth of Baxter International stock and bought 178,227 units worth 6,261,495$ . The most active insiders traders include Point Llc Loeb Daniel S Third、Michael F Mahoney、Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of 3,609,738$. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth 2,397,019$.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: